DDDaniel Duerschmied

Daniel Duerschmied

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel Duerschmied has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Christoph Bode

    Department of Cardiology and Angiology I, Heart Center Freiburg University, Freiburg, Germany

    6 shared publications
  • Christoph Bode

    Department of Cardiology and Angiology I, Heart Center Freiburg University, Freiburg, Germany

    4 shared publications
  • Tobias Wengenmayer

    Interdisziplinäre Medizinische Intensivtherapie, Universitätsklinik der Albert-Ludwigs-Universität Freiburg, Freiburg, Deutschland

    4 shared publications
  • Alex Supady

    Department of Cardiology and Angiology I, Heart Center Freiburg University, Freiburg, Germany

    3 shared publications
  • C. Bode

    Department of Cardiology and Angiology I, University Heart Center Freiburg, Freiburg, Germany

    3 shared publications
  • Christoph Benk

    Department of Cardiovascular Surgery, Heart Center Freiburg University, Freiburg, Germany

    3 shared publications

Latest Publications

  • Open Access

    Thrombelastography Compared with Multiple Impedance Aggregometry to Assess High On-Clopidogrel Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

    by Diona Gjermeni, Hannah Vetter, Sofia Szabó, Viktoria Anfang, Stefan Leggewie, David Hesselbarth, Daniel Duerschmied, Dietmar Trenk, Christoph B. Olivier

    Background: High on-clopidogrel platelet reactivity (HPR) following percutaneous coronary intervention (PCI) is associated with increased ischemic risk. It is unclear whether conventional definitions of HPR apply to patients with concomitant oral anticoagulation (OAC). This study aimed to compare the performance of multiple platelet aggregometry (MEA) and thrombelastography (TEG) to detect HPR in patients with atrial fibrillation (AF) and indication for an OAC. Methods: In this observational single-center cohort study, MEA and TEG were performed in patients with AF with an indication for OAC on day 1 to 3 after PCI. The primary outcome was HPR as assessed by MEA (ADP area under the curve ≥ 46 units [U]) or TEG (MAADP ≥ 47 mm), respectively. The secondary exploratory outcomes were a composite of all-cause death, myocardial infarction (MI) or stroke and bleeding, as defined by the International Society on Thrombosis and Hemostasis, at 6 months. Results: Platelet function of 39 patients was analyzed. The median age was 78 (interquartile range [IQR] was 72–82) years. 25 (64%) patients were male, and 19 (49%) presented with acute coronary syndrome. All patients received acetylsalicylic acid and clopidogrel prior to PCI. Median (IQR) ADP-induced aggregation, MAADP, TRAP-induced aggregation, and MAthrombin were 9 (6–15) U, 50 (43–60) mm, 54 (35–77) U and 65 (60–67) mm, respectively. The rate of HPR was significantly higher if assessed by TEG compared with MEA (25 [64%] vs. 1 [3%]; p < 0.001). Within 6 months, four (10%) deaths, one (3%) MI and nine (23%) bleeding events occurred. Conclusion: In patients with AF undergoing PCI, the rates of HPR detected by TEG were significantly higher compared with MEA. Conventional cut-off values for HPR as proposed by consensus documents may need to be re-evaluated for this population at high ischemic and bleeding risk. Further studies are needed to assess the association with outcomes.


  • Open Access

    On the Use of Hemadsorption with CytoSorb in Patients with Septic Shock. Comment on Kogelmann et al. First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of Adjuvant CytoSorb Hemoadsorption Therapy in Patients with Septic Shock. J. Clin. Med. 2021, 10, 2939

    by Alexander Supady, Philipp M. Lepper, Daniel Duerschmied, Tobias Wengenmayer

    With great interest we read the article by Klaus Kogelmann and co-authors on the “First Evaluation of a New Dynamic Scoring System Intended to Support Prescription of Adjuvant CytoSorb Hemoadsorption Therapy in Patients with Septic Shock”


  • Open Access

    Use and Outcomes of Acute Treatment Strategies in Patients with Severe Aortic Valve Stenosis

    by Sven M. Piepenburg, Klaus Kaier, Christoph B. Olivier, Wolfgang Bothe, Timo Heidt, Markus Jäckel, Alexander Peikert, Dennis Wolf, Manfred Zehender, Christoph Bode, et al.

    This study aimed to evaluate the acute treatment of patients with severe aortic valve stenosis in Germany. Three treatment strategies in 11,027 patients acutely admitted due to aortic valve stenosis were compared from 2014 until 2018 using German nationwide records: The annual number of transcatheter aortic valve replacement (TAVR) procedures (1,294 to 1,827) and balloon valvuloplasty (BV only) procedures (170 to 233) in patients acutely admitted increased, but surgical aortic valve replacement (SAVR) procedures decreased (426 to 316). In comparison to BV only patients (mean age 81.3; EuroSCORE 23.2) SAVR patients were younger and at lower logistic EuroSCORE (mean age 66.9; EuroSCORE 9.4). Patients treated with TAVR were at comparable age and operative risk (mean age 81.3; EuroSCORE 24.4) as those patients treated with BV only. Primary outcome was in-hospital mortality. Reimbursement was considered secondary outcome. After risk adjustment using multivariable logistic and linear regression analyses, SAVR (OR 0.26 [96%CI 0.16;0.45], p < 0.001) and TAVR (OR 0.38 [0.29;0.49], p < 0.001) were associated with lower risk for mortality compared to BV only. Compared to BV only, hospitalization costs of patients undergoing SAVR were reduced by €5,578 ([95%CI €8,023; €3,133], p < 0.001). TAVR procedures were associated with higher hospitalization costs than BV only (risk-adjusted difference €4,143 [€2,330; €5,926], p < 0.001). BV only was associated with a substantially increased risk of in-hospital mortality in acute patients. We conclude that a definitive aortic valve replacement should be preferred as primary treatment in patients with severe aortic valve stenosis causing an acute admission.


  • Open Access

    P2Y12 Inhibition in Murine Myocarditis Results in Reduced Platelet Infiltration and Preserved Ejection Fraction

    by Sarah Nasreen Schmidt, Wilfried Reichardt, Beat A. Kaufmann, Carolin Wadle, Dominik von Elverfeldt, Peter Stachon, Ingo Hilgendorf, Dennis Wolf, Timo Heidt, Daniel Duerschmied, et al.

    Previous mouse studies have shown the increased presence of platelets in the myocardium during early stages of myocarditis and their selective detection by MRI. Here, we aimed to depict early myocarditis using molecular contrast-enhanced ultrasound of activated platelets, and to evaluate the impact of a P2Y12 receptor platelet inhibition. Experimental autoimmune myocarditis was induced in BALB/c mice by subcutaneous injection of porcine cardiac myosin and complete Freund adjuvant (CFA). Activated platelets were targeted with microbubbles (MB) coupled to a single-chain antibody that binds to the “ligand-induced binding sites” of the GPIIb/IIIa-receptor (=LIBS-MB). Alongside myocarditis induction, a group of mice received a daily dose of 100 g prasugrel for 1 month. Mice injected with myosin and CFA had a significantly deteriorated ejection fraction and histological inflammation on day 28 compared to mice only injected with myosin. Platelets infiltrated the myocardium before reduction in ejection fraction could be detected by echocardiography. No selective binding of the LIBS-MB contrast agent could be detected by either ultrasound or histology. Prasugrel therapy preserved ejection fraction and significantly reduced platelet aggregates in the myocardium compared to mice without prasugrel therapy. Therefore, P2Y12 inhibition could be a promising early therapeutic target in myocarditis, requiring further investigation.


  • Performance of SOFA, SAVE, and SAPS2 score in venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock and extracorporeal cardiopulmonary resuscitation (eCPR)

    by Dawid Staudacher, Alex Supady, Florentine Schroth, Daniel Duerschmied, Christoph Benk, Paul Biever, Christoph Bode, Tobias Wengenmayer


  • Impact of arterial and venous cannula diameter in venoarterial extracorporeal membrane oxygenation (VA-ECMO)

    by Alex Supady, Tobias Wengenmayer, Florentine Schroth, Daniel Duerschmied, Christoph Benk, Christoph Bode, Dawid Staudacher

  • Vasopressor doses correlate with survival VA ECMO patients within the first 7 days

    by Tobias Wengenmeyer, Alex Supady, Paul Biever, Daniel Duerschmied, Florentine Schroth, Christoph Benk, Christoph Bode, Dawid Staudacher


  • Autocrine and paracrine regulatory functions of platelet serotonin

    by Elmina Mammadova-Bach, Maximilian Mauler, Attila Braun, Daniel Duerschmied

    Platelets serotonin (5-hydroxytrytamine, 5-HT) uptake and storage in dense granules is tightly regulated by the serotonergic transport system in the blood. Several 5-HT transporters (5-HTTs) have been identified in the vasculature and blood cells, beyond them 5-HTT is the major 5-HT transporter in platelets. Abnormal 5-HT concentrations in the blood plasma or increased platelet 5-HT uptake or abnormal release contribute to the development of various diseases in the vasculature. Consequently, several clinical trials suggested the positive therapeutic effects of 5-HTT blockade in the circulation. Inhibition of 5-HT strongly attenuates autocrine and paracrine functions of platelets, influencing platelet aggregation, vascular contraction, permeability, tissue repair, wound healing, immunity and cancer. Here, we highlight the current state of basic biological research regarding the hemostatic and non-hemostatic functions of platelet-derived 5-HT in normal and disease conditions. We also describe the physiological consequences of targeting platelet 5-HT functions in thrombosis, stroke, inflammation and cancer to overcome common health problems.


  • Top Cited Papers
    Open Access

    Influence of low-flow time on survival after extracorporeal cardiopulmonary resuscitation (eCPR)

    by Tobias Wengenmayer, Stephan Rombach, Florian Ramshorn, Paul Biever, Christoph Bode, Daniel Duerschmied, Dawid L. Staudacher

    Venoarterial extracorporeal membrane oxygenation (VA-ECMO) support under extracorporeal cardiopulmonary resuscitation (eCPR) is the last option and may be offered to selected patients. Several factors predict outcome in these patients, including initial heart rhythm, comorbidities, and bystander cardiopulmonary resuscitation (CPR). We evaluated outcomes of all VA-ECMO patients treated within the last 5 years at our center in respect to low-flow duration during CPR. We report retrospective registry data on all patients with eCPR treated at a university hospital between October 2010 and May 2016. A total of 133 patients (mean age 58.7 ± 2.6 years, Simplified Acute Physiology Score II score at admission 48.1 ± 3.4) were included in the analysis. The indication for eCPR was either in-hospital or out-of-hospital cardiac arrest without return of spontaneous circulation (n = 74 and 59, respectively). There was a significant difference in survival rates between groups (eCPR in-hospital cardiac arrest [IHCA] 18.9%, eCPR out-of-hospital cardiac arrest [OHCA] 8.5%; p < 0.042). Mean low-flow duration (i.e., duration of mechanical CPR until VA-ECMO support) was 59.6 ± 5.0 minutes in all patients and significantly shorter in IHCA patients than in OHCA patients (49.6 ± 5.9 vs. 72.2 ± 7.4 minutes, p = 0.001). Low-flow time strongly correlated with survival (p < 0.001) and was an independent predictor of mortality. Time to full support is an important and alterable predictor of patient survival in eCPR, suggesting that VA-ECMO therapy should be established as fast as possible in the selected patients destined for eCPR.


  • Open Access

    Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition

    by F. Guenther, N. Herr, M. Mauler, T. Witsch, F. Roming, L. Hein, J.-M. Boeynaems, B. Robaye, M. Idzko, C. Bode, et al.